KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Long-Term Investments (2016 - 2025)

Astrazeneca has reported Long-Term Investments over the past 11 years, most recently at $498.0 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $498.0 million for Q4 2025, up 85.82% from a year ago — trailing twelve months through Dec 2025 was $498.0 million (up 85.82% YoY), and the annual figure for FY2025 was $498.0 million, up 85.82%.
  • Long-Term Investments for Q4 2025 was $498.0 million at Astrazeneca, up from $268.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for AZN hit a ceiling of $1.1 billion in Q4 2022 and a floor of $69.0 million in Q4 2021.
  • Median Long-Term Investments over the past 5 years was $268.0 million (2024), compared with a mean of $409.6 million.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 1444.93% in 2022 and later crashed 86.21% in 2023.
  • Astrazeneca's Long-Term Investments stood at $69.0 million in 2021, then skyrocketed by 1444.93% to $1.1 billion in 2022, then crashed by 86.21% to $147.0 million in 2023, then soared by 82.31% to $268.0 million in 2024, then soared by 85.82% to $498.0 million in 2025.
  • The last three reported values for Long-Term Investments were $498.0 million (Q4 2025), $268.0 million (Q4 2024), and $147.0 million (Q4 2023) per Business Quant data.